ICIs are antibodies that target specific immune checkpoints like cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1), or its ligand (PD-L1), leading to T-cell activation and antitumor activity. These inhibitors have become a powerful tool for oncologists and are now widely used to treat various cancers, including melanom
1570 Reached2 Comments3 Likes
Complicated case of Osteoarthritis
1850 Reached2 Comments3 Likes
Black Lesion in Old Female
1974 Reached5 Comments11 Likes
Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes
Case of Adolescent with Severe Macrocytic Anaemia
53214 Reached503 Comments51 Likes
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes